BSE See NSE See 52,588.71
14.25 (0.03%)

Cipla gains post making deal with Roche for selling drug effective for COVID patients

Ganesh V
/ Categories: Mindshare
Rate this article:
Cipla gains post making deal with Roche for selling drug effective for COVID patients

Roche India recently announced that Central Drugs Standards Control Organisation (CDSCO) has provided an emergency use authorisation (EUA) for Roche’s antibody cocktail (Casirivimab & Imdevimab) in India.  

Casirivimab and Imdevimab are indicated for the treatment of mild to moderate COVID-19 in high-risk patients. Cipla will market & distribute the product in India. The drug will be available in leading hospitals and COVID-treatment centres.  

Reacting to this, the company’s stock today increased by 3.13 per cent and made an intraday high of Rs 916.50 per share. The stock of the company has increased by 55.50 per cent from its decline in May 2020.  

The company reported a net profit of Rs 752.51 crore in Q3FY21. In Q3FY20, it had reported a profit of Rs 353.58 crore, which is an increase of 112.83 per cent. The company reported net sales of Rs 5,154.17 crore for Q3FY21, an increase of 21.72 per cent as against the net sales of Rs 4,234.55 crore for Q3FY20. 

Roche Products (India) Private Limited is a wholly-owned subsidiary of Roche Group, headquartered in Basel (Switzerland). Roche provides medicines in oncology, immunology, infectious diseases, ophthalmology, and diseases of the central nervous system.    

According to BSE data, the stock traded at a P/E multiple of 26.95 and a price-to-book ratio of 3.80. The stock has a 52-week high and a 52-week low of Rs 966 and Rs 565.90, respectively.     

The stock of Cipla Ltd ended in red on Thursday i.e. down by 0.55 per cent at Rs 883.80.

Previous Article JB Chemicals zooms over 2 per cent on launching Renova division
Next Article Stocks likely to buzz on bourses today
Please login or register to post comments.

Get A Call From Industry Experts

Send Otp

   I authorize DSIJ Pvt Ltd to contact me. This will override registry on the NDNC.


NASDAQ hits all time high; S&P 500 near life highs while Bitcoin turn positive after massive price drop!

In midst of the chaos that is taking place in the crypto currency world NASDAQ just managed to hit an all-time high for itself. The S&P 500 is precariously poised to make its record highs as is trades just half a percent below its life highs.

Yogesh Supekar / Article rating: 5.0
NASDAQ Composite is a tech-heavy index and has been a world beating index in 2020. In 2021 so far NASDAQ has underperformed S&P 500 and even...